FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* CASH W LARRY (Last) (First) (Middle)					[2. Issuer Name and Ticker or Trading Symbol COMMUNITY HEALTH SYSTEMS INC [CYH] 3. Date of Earliest Transaction (Month/Day/Year)								ationship of all applicat Director Officer (g below)	ble)	Person(s) to I 10% C Other (below)	wner (specify	
4000 MERIDIAN BOULEVARD						03/01/2017								President and CFO				
(Street) FRANKLIN (City)	TN					4. If Amendment, Date of Original Filed (Month/Day/Year)								Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Oity)	(Otate			lon Do	rivati		Socuriti	ios Ac	nuirod	Die	nosod of	f or Bon	oficially	Owned				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				saction	ion 2A. Deemed Execution Date,		ed n Date,	3. Transaction Code (Instr.		4. Securities Acquired (Disposed Of (D) (Instr. 3 and 5)		ed (A) or	5. Amount Securities Beneficiall Owned	ly (6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Following Reported Transactio (Instr. 3 an	on(s)	Instr. 4)	(Instr. 4)	
Common Stock 03/0						017		М		75,000) A	\$0.00	604,5	91	D			
Common Stock 03/01/2					1/2017	017		A		16,000	(1) A	\$0.00	620,591		D			
Common Stock 03/0				03/0	1/2017	/2017					52,439	D	\$9.19	568,152		D		
			Tabl								sed of, or nvertible			ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year) any			4. Transaction Code (Instr. 8)		5. Number of Derivative		6. Date Exercisal Expiration Date (Month/Day/Yea		le and	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	÷	Expiration Date	Title	Amount of Number of Shares		Reported Transactio (Instr. 4)	on(s)		
Performance Based Restricted	\$0.00	03/01/2017			M ⁽²⁾			75,000	03/01/20	017	02/28/2026	Common Stock	75,000	\$0.00	0	D		
Performance Based Restricted	\$0.00	03/01/2017			A		16,000		03/01/202	20(3)	02/28/2027	Common Stock	16,000	\$0.00	16,000) D		
Stock Options (Right to Buy)	\$28.7								02/27/20	009	02/26/2018	Common Stock	60,000		60,000) D		
Stock Options (Right to Buy)	\$15.01								02/25/20	010	02/24/2019	Common Stock	10,000		10,000) D		
Stock Options (Right to Buy)	\$30.32								02/24/20	011	02/23/2020	Common Stock	25,000		25,000) D		
Stock Options (Right to Buy)	\$34.38					Г			02/23/20)12	02/22/2021	Common Stock	25,000		25,000) D		
Stock Options			_			1				_		Common	_		1	_	1	

Explanation of Responses:

- 1. The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant.
- 2. The performance objectives governing these shares of Performance Based Restricted Stock have been met, and, accordingly, these shares will now be reported in Table 1 as directly owned shares of Restricted Stock. The time-vesting restrictions lapse in 1/3 increments on the first, second and third anniversary of the date of grant.
- 3. The vesting of 80% of these performance-based restricted shares is subject to the attainment of a pre-determined level of Cumulative Same-Store Adjusted EBITDA Growth between January 1, 2017 and December 31, 2019 (the "Performance Period"). The vesting of the remaining 20% of these performance-based restricted shares is subject to the attainment of a pre-determined level of Cumulative Adjusted EPS for the Performance Period. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the target number of performance-based restricted shares subject to the attainment of the Cumulative Same-Store Adjusted EBITDA Growth and Cumulative Adjusted EPS criteria, as applicable, will ultimately vest on the third anniversary of the date of grant, with the vesting percentage to be determined based upon achievement with respect to the applicable criteria during the Performance Period.

Remarks

NOTE: The per share exercise price of each option listed on Table II granted prior to April 29, 2016, was adjusted pursuant to the Employee Matters Agreement between the Issuer and Quorum Health Corporation ("QHC"), dated as of April 29, 2016, to preserve the aggregate intrinsic value of the original award as a result of the spin-off from the Issuer of QHC, effective April 29, 2016.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.